Analyzing Alnylam Pharmaceuticals (NASDAQ:ALNY) & Its Peers

Alnylam Pharmaceuticals (NASDAQ: ALNY) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Alnylam Pharmaceuticals to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.

Risk and Volatility

Alnylam Pharmaceuticals has a beta of 2.98, suggesting that its share price is 198% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals’ peers have a beta of 1.46, suggesting that their average share price is 46% more volatile than the S&P 500.


This table compares Alnylam Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals -664.70% -46.94% -35.58%
Alnylam Pharmaceuticals Competitors -4,372.56% -466.93% -41.78%

Earnings and Valuation

This table compares Alnylam Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alnylam Pharmaceuticals $47.16 million -$410.10 million -24.58
Alnylam Pharmaceuticals Competitors $217.40 million -$39.40 million -63.84

Alnylam Pharmaceuticals’ peers have higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Alnylam Pharmaceuticals and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals 3 3 14 1 2.62
Alnylam Pharmaceuticals Competitors 665 2523 6742 134 2.63

Alnylam Pharmaceuticals currently has a consensus target price of $128.65, indicating a potential downside of 0.33%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.89%. Given Alnylam Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals has less favorable growth aspects than its peers.

Institutional and Insider Ownership

88.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.3% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Alnylam Pharmaceuticals beats its peers on 7 of the 13 factors compared.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply